How to identify unmet medical need with Tempus RWD

Transforming R&D with Generative AI and Real-World Data

Mike Yasiejko, General Manager and Executive Vice President at Tempus, recently spoke with Andrew Mazar, PhD, Chief Operating Officer at Actuate Therapeutics, about the ways Tempus’ liquid biopsy (xF+) and methylation assays have been valuable to Actuate’s work and how the company has benefitted from the partnership

Watch now

AI & ML in action: Demonstrating real-world impact in trial design & patient care

Discover how the Tempus platform leverages AI and ML to inform standard of care practices through health equity guidelines and drive insights that help refine clinical trial design. Engage with live demonstrations showcasing how our tools identify patients by modifying inclusion/exclusion criteria and leveraging patient queries. Explore how our tools integrate NCCN guidelines and empower life science teams to access current, actionable patient-journey insights. Learn how these real-world applications can drive progress in your clinical development initiatives.

Secure your recording now.

Watch replay

Bridging the translational gap: The role of organoids in oncology R&D

This white paper explores the evolving role of organoids in oncology R&D, highlighting their potential as predictive preclinical models and their ability to reduce translational risk. Download for a comprehensive overview of the scientific landscape, key adoption barriers, emerging innovations, and how pharma companies leverage organoids to accelerate precision medicine.

Read more